Combined BRAF-MEK inhibition better than single-agent therapy in MM

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Several recent randomized clinical trials have demonstrated that initial targeted therapy with combined BRAF and MEK inhibition is more effective in metastatic melanoma (MM) than single agent. A recent comprehensive meta-analysis confired that concurrent inhibition of BRAF and MEK was the most ...